Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 GeneticVariation group BEFREE To investigate the association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance (CR) in patients with cardiovascular disease in Beijing district. 29350207 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 GeneticVariation group BEFREE These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid. 29023376 2017
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 GeneticVariation group BEFREE Approximately, 59.0% of Korean patients with cardiovascular disease receiving clopidogrel had CYP2C19 loss-of-function genotypes classified as IM or PM, and the frequency was similar to the data from Asian people. 26522758 2016
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 GeneticVariation group BEFREE CYP2C19 genetic polymorphisms influence clopidogrel response and clinical outcomes of cardiovascular disease. 25489921 2015
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 GeneticVariation group BEFREE The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. 24782221 2014
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 Biomarker group BEFREE In this medium-size group of patients with stable CHD homozygous carriers of the loss-of-function allele CYP2C19*2 were at increased risk for subsequent CVD events during 8 year follow-up independent of other risk factors. 23981380 2013
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 Biomarker group BEFREE Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. 22757746 2013
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 Biomarker group BEFREE Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease. 23074110 2012
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 GeneticVariation group BEFREE Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 22088980 2011
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.390 Biomarker group CTD_human Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 20978260 2010